Increased serum levels of quinolinic acid indicate enhanced severity of hepatic dysfunction in patients with liver cirrhosis

• Verfasst von: Lahdou, Imad [VerfasserIn]
• Verfasst von: Sadeghi, Mahmoud [VerfasserIn]
• Verfasst von: Oweira, Hani [VerfasserIn]
• Verfasst von: Fusch, Gerhard [VerfasserIn]
• Verfasst von: Daniel, Volker [VerfasserIn]
• Verfasst von: Mehrabi, Arianeb [VerfasserIn]
• Verfasst von: Jung, Gregor Eric [VerfasserIn]
• Verfasst von: Elhadedy, Hazem [VerfasserIn]
• Verfasst von: Schmidt, Jan [VerfasserIn]
• Verfasst von: Şandra-Petrescu, Flavius Ionuţ [VerfasserIn]
• Verfasst von: Iancu, Mircea [VerfasserIn]
• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Verfasst von: Terness, Peter [VerfasserIn]
• Verfasst von: Schefold, Joerg C. [VerfasserIn]
• Titel: Increased serum levels of quinolinic acid indicate enhanced severity of hepatic dysfunction in patients with liver cirrhosis
• Verf.angabe: Imad Lahdou, Mahmoud Sadeghi, Hani Oweira, Gerhard Fusch, Volker Daniel, Arianeb Mehrabi, GE. Jung, Hazem Elhadedy, Jan Schmidt, Flavius Sandra-Petrescu, Mircea Iancu, Gerhard Opelz, Peter Terness, Joerg C. Schefold
• Jahr: 2013
• Umfang: 7 S.
• Fussnoten: Available online 6 October 2012 ; Gesehen am 21.09.2021
• Titel Quelle: Enthalten in: Human immunology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1980
• Jahr Quelle: 2013
• Band/Heft Quelle: 74(2013), 1 vom: Jan., Seite 60-66
• ISSN Quelle: 1879-1166
• DOI: doi:10.1016/j.humimm.2012.09.009
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1582286531

Abstract

Background: The Model for End-Stage Liver Disease (MELD) score is a tool for assessment of the degree of hepatic insufficiency/failure. Quinolinic acid (QuinA) is a tryptophan metabolite produced by activated macrophages. Here we investigate whether the degree of systemic inflammation (QuinA, neopterin, CRP and IL-6) correlates with clinical liver dysfunction according to the MELD Score. Method: Ninety-four patients with liver cirrhosis were categorized into 2 groups according to baseline MELD score (group I, MELD <20, n=61, and group II, MELD ⩾20, n=33). Results: Serum levels of QuinA, neopterin, CRP, and IL-6 significantly correlated with MELD score (r=0.77, 0.75, 0.57, and 0.50; p<0.0001, respectively). Patients of group II had significantly higher serum levels of QuinA, neopterin, CRP, and IL-6 than group I (p⩽0.0001). ROC curve analysis showed that QuinA and neopterin are more sensitive markers for severity of liver disease than established markers of inflammation such as CRP and IL-6 (sensitivity=86% and 79%, respectively) (AUC=0.89 and 0.89, respectively). QuinA provided the most sensitive index with regard to the identification of patients with hepatic encephalopathy. Conclusion: Serum levels of QuinA reflect the degree of liver dysfunction. Moreover, high levels of QuinA may serve as a sensitive indicator of hepatic encephalopathy.